{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:07:51Z","timestamp":1790957271114,"version":"4.1.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T00:00:00Z","timestamp":1657584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T00:00:00Z","timestamp":1657584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK059637"],"award-info":[{"award-number":["DK059637"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"NCATS","doi-asserted-by":"crossref","award":["TR001728"],"award-info":[{"award-number":["TR001728"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Liver pathology (LP) characteristic of non-alcoholic fatty acid disease (NAFLD)\/non-alcoholic steatohepatitis (NASH) is a prevalent co-morbidity of type 2 diabetes (T2D). Accumulating evidence indicates that neutrophils driving insulin resistance (IR), including hepatic IR, precipitate T2D-associated NAFLD\/NASH. We hypothesized that targeting neutrophil accumulation into insulin-sensitive tissues in mice using a CXCR2 antagonist under T2D-precipitating high fat diet (HFD) could improve insulin sensitivity and prevent the progression towards liver pathology reminiscent of NAFLD\/NASH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Mice were age-matched and on standard rodent chow prior to 1:1 randomization into control and HFD formulated with the CXCR2 antagonist AZD5069 or with biologically inactive substitute. They were monitored for metabolic changes including insulin sensitivity using the hyperinsulinemic-euglycemic clamp and hepatic histopathologic evaluation in H&amp;E-stained sections as well as via immunofluorescence microscopy of liver sections for leukocyte markers, collagen 1A1 formation, \u03b1-smooth muscle actin (SMA), and galectin-3 expression, for 16\u00a0weeks. Statistical tests used to determine significant differences among study groups and outcomes include Student\u2019s t-test, one-way ANOVA, repeated measures two-way ANOVA, and Fisher\u2019s exact test, depending on the analytical question.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Compared to mice on HFD, mice in the AZD5069-formulated HFD exhibited improved insulin sensitivity, a modest reduction in weight gain, and a significant improvement in LP and markers related to NAFLD\/NASH. Mice in the AZD5069-formulated HFD also exhibited reduced neutrophil accumulation into the liver at the end of the 16\u00a0week study period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These results show, for the first time, the effectiveness of a selective CXCR2 antagonist to improve insulin sensitivity, concomitantly preventing the progression towards LP characteristic of NAFLD\/NASH. This represents a novel approach to target IR and developing LP under T2D-susceptible conditions using a single agent. Furthermore, our data extend the growing evidence in support of neutrophils as a leukocyte population that imprints and maintains a chronic inflammatory state in the progression of dysregulated metabolism in liver-specific co-morbid conditions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12933-022-01564-y","type":"journal-article","created":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T05:08:01Z","timestamp":1657688881000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Improvement in insulin sensitivity and prevention of high fat diet-induced liver pathology using a CXCR2 antagonist"],"prefix":"10.1186","volume":"21","author":[{"given":"Brett E.","family":"Phillips","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Lantier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Engman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yesica","family":"Garciafigueroa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aatur","family":"Singhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Trucco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Mantzoros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wasserman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Giannoukakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,12]]},"reference":[{"issue":"13","key":"1564_CR1","doi-asserted-by":"publisher","first-page":"6862","DOI":"10.3390\/ijms22136862","volume":"22","author":"TW Kao","year":"2021","unstructured":"Kao TW, Huang CC. Recent progress in metabolic syndrome research and therapeutics. Int J Mol Sci. 2021;22(13):6862.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"1564_CR2","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.3390\/nu11071529","volume":"11","author":"I Perez-Torres","year":"2019","unstructured":"Perez-Torres I, Gutierrez-Alvarez Y, Guarner-Lans V, Diaz-Diaz E, Manzano Pech L. Caballero-chacon SDC: intra-abdominal fat adipocyte hypertrophy through a progressive alteration of lipolysis and lipogenesis in metabolic syndrome rats. Nutrients. 2019;11(7):1529.","journal-title":"Nutrients"},{"issue":"4","key":"1564_CR3","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.aohep.2020.03.001","volume":"19","author":"A Lonardo","year":"2020","unstructured":"Lonardo A, Mantovani A, Lugari S, Targher G. Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity. Ann Hepatol. 2020;19(4):359\u201366.","journal-title":"Ann Hepatol"},{"issue":"4","key":"1564_CR4","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1159\/000440905","volume":"67","author":"OK Kim","year":"2015","unstructured":"Kim OK, Jun W, Lee J. Mechanism of ER stress and inflammation for hepatic insulin resistance in obesity. Ann Nutr Metab. 2015;67(4):218\u201327.","journal-title":"Ann Nutr Metab"},{"issue":"3","key":"1564_CR5","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3390\/cells8030227","volume":"8","author":"M Trojnar","year":"2019","unstructured":"Trojnar M, Patro-Malysza J, Kimber-Trojnar Z, Leszczynska-Gorzelak B. Mosiewicz J: associations between fatty acid-binding protein 4(-)A proinflammatory adipokine and insulin resistance, gestational and type 2 diabetes mellitus. Cells. 2019;8(3):227.","journal-title":"Cells"},{"issue":"3","key":"1564_CR6","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1016\/j.bbrc.2018.07.090","volume":"503","author":"Y Yang","year":"2018","unstructured":"Yang Y, Lu Y, Han F, Chang Y, Li X, Han Z, Xue M, Cheng Y, Sun B, Chen L. Saxagliptin regulates M1\/M2 macrophage polarization via CaMKKbeta\/AMPK pathway to attenuate NAFLD. Biochem Biophys Res Commun. 2018;503(3):1618\u201324.","journal-title":"Biochem Biophys Res Commun"},{"issue":"11","key":"1564_CR7","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1161\/CIRCRESAHA.120.316203","volume":"126","author":"A Weinstock","year":"2020","unstructured":"Weinstock A, Moura Silva H, Moore KJ, Schmidt AM, Fisher EA. Leukocyte heterogeneity in adipose tissue including in obesity. Circ Res. 2020;126(11):1590\u2013612.","journal-title":"Circ Res"},{"issue":"6","key":"1564_CR8","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1172\/JCI57132","volume":"121","author":"CN Lumeng","year":"2011","unstructured":"Lumeng CN, Saltiel AR. Inflammatory links between obesity and metabolic disease. J Clin Invest. 2011;121(6):2111\u20137.","journal-title":"J Clin Invest"},{"issue":"1","key":"1564_CR9","first-page":"1","volume":"14","author":"Z Michailidou","year":"2021","unstructured":"Michailidou Z, Gomez-Salazar M. Alexaki VI: innate immune cells in the adipose tissue in health and metabolic disease. J Innate Immun. 2021;14(1):1\u201327.","journal-title":"J Innate Immun"},{"key":"1564_CR10","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3389\/fphys.2018.00113","volume":"9","author":"C Rosales","year":"2018","unstructured":"Rosales C. Neutrophil: a cell with many roles in inflammation or several cell types? Front Physiol. 2018;9:113.","journal-title":"Front Physiol"},{"issue":"3","key":"1564_CR11","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.bbadis.2013.05.017","volume":"1842","author":"BC Lee","year":"2014","unstructured":"Lee BC, Lee J. Cellular and molecular players in adipose tissue inflammation in the development of obesity-induced insulin resistance. Biochim Biophys Acta. 2014;1842(3):446\u201362.","journal-title":"Biochim Biophys Acta"},{"issue":"9","key":"1564_CR12","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1038\/nm.2885","volume":"18","author":"S Talukdar","year":"2012","unstructured":"Talukdar S, Oh DY, Bandyopadhyay G, Li D, Xu J, McNelis J, Lu M, Li P, Yan Q, Zhu Y, et al. Neutrophils mediate insulin resistance in mice fed a high-fat diet through secreted elastase. Nat Med. 2012;18(9):1407\u201312.","journal-title":"Nat Med"},{"issue":"1","key":"1564_CR13","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s12020-017-1323-4","volume":"57","author":"R Ou","year":"2017","unstructured":"Ou R, Liu J, Lv M, Wang J, Wang J, Zhu L, Zhao L, Xu Y. Neutrophil depletion improves diet-induced non-alcoholic fatty liver disease in mice. Endocrine. 2017;57(1):72\u201382.","journal-title":"Endocrine"},{"issue":"4","key":"1564_CR14","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1159\/000350282","volume":"5","author":"N Strydom","year":"2013","unstructured":"Strydom N, Rankin SM. Regulation of circulating neutrophil numbers under homeostasis and in disease. J Innate Immun. 2013;5(4):304\u201314.","journal-title":"J Innate Immun"},{"issue":"1","key":"1564_CR15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/path.4555","volume":"237","author":"CW Steele","year":"2015","unstructured":"Steele CW, Karim SA, Foth M, Rishi L, Leach JD, Porter RJ, Nixon C, Jeffry Evans TR, Carter CR, Nibbs RJ, et al. CXCR2 inhibition suppresses acute and chronic pancreatic inflammation. J Pathol. 2015;237(1):85\u201397.","journal-title":"J Pathol"},{"issue":"31","key":"1564_CR16","doi-asserted-by":"publisher","first-page":"20692","DOI":"10.1074\/jbc.M109.018556","volume":"284","author":"JG Neels","year":"2009","unstructured":"Neels JG, Badeanlou L, Hester KD, Samad F. Keratinocyte-derived chemokine in obesity: expression, regulation, and role in adipose macrophage infiltration and glucose homeostasis. J Biol Chem. 2009;284(31):20692\u20138.","journal-title":"J Biol Chem"},{"issue":"2","key":"1564_CR17","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1530\/JOE-14-0126","volume":"222","author":"CS Nunemaker","year":"2014","unstructured":"Nunemaker CS, Chung HG, Verrilli GM, Corbin KL, Upadhye A, Sharma PR. Increased serum CXCL1 and CXCL5 are linked to obesity, hyperglycemia, and impaired islet function. J Endocrinol. 2014;222(2):267\u201376.","journal-title":"J Endocrinol"},{"issue":"9","key":"1564_CR18","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1038\/sj.ijo.0803259","volume":"30","author":"CS Kim","year":"2006","unstructured":"Kim CS, Park HS, Kawada T, Kim JH, Lim D, Hubbard NE, Kwon BS, Erickson KL, Yu R. Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters. Int J Obes. 2006;30(9):1347\u201355.","journal-title":"Int J Obes"},{"issue":"Suppl 2","key":"1564_CR19","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.2337\/diabetes.54.suppl_2.S11","volume":"54","author":"C Herder","year":"2005","unstructured":"Herder C, Haastert B, Muller-Scholze S, Koenig W, Thorand B, Holle R, Wichmann HE, Scherbaum WA, Martin S, Kolb H. Association of systemic chemokine concentrations with impaired glucose tolerance and type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg Survey S4 (KORA S4). Diabetes. 2005;54(Suppl 2):S11-17.","journal-title":"Diabetes"},{"issue":"10","key":"1564_CR20","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S2213-2600(16)30227-2","volume":"4","author":"PM O'Byrne","year":"2016","unstructured":"O\u2019Byrne PM, Metev H, Puu M, Richter K, Keen C, Uddin M, Larsson B, Cullberg M, Nair P. Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2016;4(10):797\u2013806.","journal-title":"Lancet Respir Med"},{"issue":"2","key":"1564_CR21","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s40268-018-0236-x","volume":"18","author":"M Cullberg","year":"2018","unstructured":"Cullberg M, Arfvidsson C, Larsson B, Malmgren A, Mitchell P, Wahlby Hamren U, Wray H. Pharmacokinetics of the oral selective CXCR2 antagonist AZD5069: a summary of eight phase I studies in healthy volunteers. Drugs R D. 2018;18(2):149\u201359.","journal-title":"Drugs R D"},{"issue":"3","key":"1564_CR22","doi-asserted-by":"publisher","first-page":"e0120092","DOI":"10.1371\/journal.pone.0120092","volume":"10","author":"GC Wilson","year":"2015","unstructured":"Wilson GC, Kuboki S, Freeman CM, Nojima H, Schuster RM, Edwards MJ, Lentsch AB. CXC chemokines function as a rheostat for hepatocyte proliferation and liver regeneration. PLoS ONE. 2015;10(3):e0120092.","journal-title":"PLoS ONE"},{"issue":"2","key":"1564_CR23","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.immuni.2019.01.009","volume":"50","author":"DP Dyer","year":"2019","unstructured":"Dyer DP, Medina-Ruiz L, Bartolini R, Schuette F, Hughes CE, Pallas K, Vidler F, Macleod MKL, Kelly CJ, Lee KM, et al. Chemokine receptor redundancy and specificity are context dependent. Immunity. 2019;50(2):378-389 e375.","journal-title":"Immunity"},{"issue":"1","key":"1564_CR24","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ajpath.2021.10.002","volume":"192","author":"M Ichimura-Shimizu","year":"2022","unstructured":"Ichimura-Shimizu M, Tsuchiyama Y, Morimoto Y, Matsumoto M, Kobayashi T, Sumida S, Kakimoto T, Oya T, Ogawa H, Yamashita M, et al. A novel mouse model of nonalcoholic steatohepatitis suggests that liver fibrosis initiates around lipid-laden macrophages. Am J Pathol. 2022;192(1):31\u201342.","journal-title":"Am J Pathol"},{"issue":"11","key":"1564_CR25","doi-asserted-by":"publisher","first-page":"3024","DOI":"10.1111\/febs.15877","volume":"289","author":"R Thibaut","year":"2021","unstructured":"Thibaut R, Gage MC, Pineda-Torra I, Chabrier G, Venteclef N, Alzaid F. Liver macrophages and inflammation in physiology and physiopathology of non-alcoholic fatty liver disease. FEBS J. 2021;289(11):3024\u201357.","journal-title":"FEBS J"},{"key":"1564_CR26","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.3389\/fimmu.2020.01169","volume":"11","author":"H Li","year":"2020","unstructured":"Li H, Zhou Y, Wang H, Zhang M, Qiu P, Zhang M, Zhang R, Zhao Q, Liu J. Crosstalk between liver macrophages and surrounding cells in nonalcoholic steatohepatitis. Front Immunol. 2020;11:1169.","journal-title":"Front Immunol"},{"issue":"5","key":"1564_CR27","doi-asserted-by":"publisher","first-page":"e12971","DOI":"10.1111\/sji.12971","volume":"92","author":"S Kragh Petersen","year":"2020","unstructured":"Kragh Petersen S, Bilkei-Gorzo O, Govaere O, Hartlova A. Macrophages and scavenger receptors in obesity-associated non-alcoholic liver fatty disease (NAFLD). Scand J Immunol. 2020;92(5):e12971.","journal-title":"Scand J Immunol"},{"issue":"3","key":"1564_CR28","first-page":"391","volume":"82","author":"M Itoh","year":"2020","unstructured":"Itoh M, Ogawa Y, Suganami T. Chronic inflammation as a molecular basis of nonalcoholic steatohepatitis: role of macrophages and fibroblasts in the liver. Nagoya J Med Sci. 2020;82(3):391\u20137.","journal-title":"Nagoya J Med Sci"},{"issue":"5","key":"1564_CR29","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.jhep.2019.06.031","volume":"71","author":"C Rosso","year":"2019","unstructured":"Rosso C, Kazankov K, Younes R, Esmaili S, Marietti M, Sacco M, Carli F, Gaggini M, Salomone F, Moller HJ, et al. Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease. J Hepatol. 2019;71(5):1012\u201321.","journal-title":"J Hepatol"},{"issue":"3","key":"1564_CR30","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41575-018-0082-x","volume":"16","author":"K Kazankov","year":"2019","unstructured":"Kazankov K, Jorgensen SMD, Thomsen KL, Moller HJ, Vilstrup H, George J, Schuppan D, Gronbaek H. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Nat Rev Gastroenterol Hepatol. 2019;16(3):145\u201359.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"1564_CR31","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1002\/hep.29630","volume":"67","author":"R Raeman","year":"2018","unstructured":"Raeman R, Anania FA. Therapy for steatohepatitis: do macrophages hold the clue? Hepatology. 2018;67(4):1204\u20136.","journal-title":"Hepatology"},{"issue":"1","key":"1564_CR32","first-page":"100","volume":"6","author":"J Grunhut","year":"2018","unstructured":"Grunhut J, Wang W, Aykut B, Gakhal I, Torres-Hernandez A, Miller G. Macrophages in nonalcoholic steatohepatitis: friend or foe? Eur Med J Hepatol. 2018;6(1):100\u20139.","journal-title":"Eur Med J Hepatol"},{"issue":"4","key":"1564_CR33","doi-asserted-by":"publisher","first-page":"133","DOI":"10.5625\/lar.2018.34.4.133","volume":"34","author":"JY Cha","year":"2018","unstructured":"Cha JY, Kim DH, Chun KH. The role of hepatic macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Lab Anim Res. 2018;34(4):133\u20139.","journal-title":"Lab Anim Res"},{"issue":"5","key":"1564_CR34","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1517\/14728222.2016.1125883","volume":"20","author":"R Wu","year":"2016","unstructured":"Wu R, Nakatsu G, Zhang X, Yu J. Pathophysiological mechanisms and therapeutic potentials of macrophages in non-alcoholic steatohepatitis. Expert Opin Ther Targets. 2016;20(5):615\u201326.","journal-title":"Expert Opin Ther Targets"},{"issue":"1","key":"1564_CR35","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.yexmp.2015.06.015","volume":"99","author":"A Jindal","year":"2015","unstructured":"Jindal A, Bruzzi S, Sutti S, Locatelli I, Bozzola C, Paternostro C, Parola M, Albano E. Fat-laden macrophages modulate lobular inflammation in nonalcoholic steatohepatitis (NASH). Exp Mol Pathol. 2015;99(1):155\u201362.","journal-title":"Exp Mol Pathol"},{"issue":"1","key":"1564_CR36","first-page":"95","volume":"56","author":"MS Jorgensen","year":"2017","unstructured":"Jorgensen MS, Tornqvist KS, Hvid H. Calculation of glucose dose for intraperitoneal glucose tolerance tests in lean and obese mice. J Am Assoc Lab Anim Sci. 2017;56(1):95\u20137.","journal-title":"J Am Assoc Lab Anim Sci"},{"issue":"12","key":"1564_CR37","doi-asserted-by":"publisher","first-page":"e0208634","DOI":"10.1371\/journal.pone.0208634","volume":"13","author":"L Lantier","year":"2018","unstructured":"Lantier L, Williams AS, Hughey CC, Bracy DP, James FD, Ansari MA, Gius D, Wasserman DH. SIRT2 knockout exacerbates insulin resistance in high fat-fed mice. PLoS ONE. 2018;13(12):e0208634.","journal-title":"PLoS ONE"},{"issue":"2","key":"1564_CR38","doi-asserted-by":"publisher","first-page":"390","DOI":"10.2337\/diabetes.55.02.06.db05-0686","volume":"55","author":"JE Ayala","year":"2006","unstructured":"Ayala JE, Bracy DP, McGuinness OP, Wasserman DH. Considerations in the design of hyperinsulinemic-euglycemic clamps in the conscious mouse. Diabetes. 2006;55(2):390\u20137.","journal-title":"Diabetes"},{"issue":"3 Pt 1","key":"1564_CR39","first-page":"E353","volume":"248","author":"EW Kraegen","year":"1985","unstructured":"Kraegen EW, James DE, Jenkins AB, Chisholm DJ. Dose-response curves for in vivo insulin sensitivity in individual tissues in rats. Am J Physiol. 1985;248(3 Pt 1):E353-362.","journal-title":"Am J Physiol"},{"issue":"1","key":"1564_CR40","doi-asserted-by":"publisher","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead P, Loughrey MB, Fernandez JA, Dombrowski Y, McArt DG, Dunne PD, McQuaid S, Gray RT, Murray LJ, Coleman HG, et al. QuPath: open source software for digital pathology image analysis. Sci Rep. 2017;7(1):16878.","journal-title":"Sci Rep"},{"issue":"5","key":"1564_CR41","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1093\/qjmed\/hcr233","volume":"105","author":"RM Williamson","year":"2012","unstructured":"Williamson RM, Price JF, Hayes PC, Glancy S, Frier BM, Johnston GI, Reynolds RM, Strachan MW. Edinburgh type 2 diabetes study i: prevalence and markers of advanced liver disease in type 2 diabetes. QJM. 2012;105(5):425\u201332.","journal-title":"QJM"},{"issue":"12","key":"1564_CR42","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1016\/j.cgh.2020.11.005","volume":"19","author":"N Tamaki","year":"2020","unstructured":"Tamaki N, Munaganuru N, Jung J, Yonan AQ, Bettencourt R, Ajmera V, Valasek MA, Behling C, Loomba R. Clinical utility of change in nonalcoholic fatty liver disease activity score and change in fibrosis in NAFLD. Clin Gastroenterol Hepatol. 2020;19(12):2673\u20134.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"1564_CR43","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.jdiacomp.2013.10.008","volume":"28","author":"L Perreault","year":"2014","unstructured":"Perreault L, Faerch K. Approaching pre-diabetes. J Diabetes Complications. 2014;28(2):226\u201333.","journal-title":"J Diabetes Complications"},{"issue":"6","key":"1564_CR44","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1210\/jc.2014-1425","volume":"99","author":"PA Halban","year":"2014","unstructured":"Halban PA, Polonsky KS, Bowden DW, Hawkins MA, Ling C, Mather KJ, Powers AC, Rhodes CJ, Sussel L, Weir GC. Beta-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment. J Clin Endocrinol Metab. 2014;99(6):1983\u201392.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"1564_CR45","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1002\/eji.201545502","volume":"45","author":"FM Wensveen","year":"2015","unstructured":"Wensveen FM, Valentic S, Sestan M, Turk Wensveen T, Polic B. The \u201cBig Bang\u201d in obese fat: events initiating obesity-induced adipose tissue inflammation. Eur J Immunol. 2015;45(9):2446\u201356.","journal-title":"Eur J Immunol"},{"issue":"6","key":"1564_CR46","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1002\/hep.30251","volume":"69","author":"Z Younossi","year":"2019","unstructured":"Younossi Z, Tacke F, Arrese M, Chander Sharma B, Mostafa I, Bugianesi E, Wai-Sun Wong V, Yilmaz Y, George J, Fan J, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2019;69(6):2672\u201382.","journal-title":"Hepatology"},{"issue":"4","key":"1564_CR47","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","volume":"71","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, Qiu Y, Burns L, Afendy A, Nader F. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71(4):793\u2013801.","journal-title":"J Hepatol"},{"issue":"1","key":"1564_CR48","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/nrgastro.2016.147","volume":"14","author":"H Tilg","year":"2017","unstructured":"Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 2017;14(1):32\u201342.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"7","key":"1564_CR49","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1172\/JCI29069","volume":"116","author":"SE Shoelson","year":"2006","unstructured":"Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006;116(7):1793\u2013801.","journal-title":"J Clin Invest"},{"issue":"1","key":"1564_CR50","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/MOH.0000000000000008","volume":"21","author":"M Battaglia","year":"2014","unstructured":"Battaglia M. Neutrophils and type 1 autoimmune diabetes. Curr Opin Hematol. 2014;21(1):8\u201315.","journal-title":"Curr Opin Hematol"},{"issue":"3","key":"1564_CR51","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1160\/TH12-09-0703","volume":"109","author":"J Chmelar","year":"2013","unstructured":"Chmelar J, Chung KJ, Chavakis T. The role of innate immune cells in obese adipose tissue inflammation and development of insulin resistance. Thromb Haemost. 2013;109(3):399\u2013406.","journal-title":"Thromb Haemost"},{"issue":"2","key":"1564_CR52","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1177\/1076029612459675","volume":"20","author":"E Buyukkaya","year":"2014","unstructured":"Buyukkaya E, Karakas MF, Karakas E, Akcay AB, Tanboga IH, Kurt M, Sen N. Correlation of neutrophil to lymphocyte ratio with the presence and severity of metabolic syndrome. Clin Appl Thromb Hemost. 2014;20(2):159\u201363.","journal-title":"Clin Appl Thromb Hemost"},{"issue":"5","key":"1564_CR53","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s40618-017-0799-3","volume":"41","author":"MG Radaelli","year":"2018","unstructured":"Radaelli MG, Martucci F, Perra S, Accornero S, Castoldi G, Lattuada G, Manzoni G, Perseghin G. NAFLD\/NASH in patients with type 2 diabetes and related treatment options. J Endocrinol Invest. 2018;41(5):509\u201321.","journal-title":"J Endocrinol Invest"},{"issue":"2 Suppl 1","key":"1564_CR54","doi-asserted-by":"publisher","first-page":"S77","DOI":"10.1016\/j.dsx.2016.01.034","volume":"10","author":"S Krishan","year":"2016","unstructured":"Krishan S. Correlation between non-alcoholic fatty liver disease (NAFLD) and dyslipidemia in type 2 diabetes. Diabetes & metabolic syndrome. 2016;10(2 Suppl 1):S77-81.","journal-title":"Diabetes & metabolic syndrome"},{"key":"1564_CR55","doi-asserted-by":"publisher","first-page":"110480","DOI":"10.1016\/j.mce.2019.110480","volume":"493","author":"M de Mendonca","year":"2019","unstructured":"de Mendonca M, Dos Santos BAC, de Sousa E, Rodrigues AC. Adiponectin is required for pioglitazone-induced improvements in hepatic steatosis in mice fed a high-fat diet. Mol Cell Endocrinol. 2019;493:110480.","journal-title":"Mol Cell Endocrinol"},{"issue":"4","key":"1564_CR56","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.cmet.2009.03.002","volume":"9","author":"C Chavey","year":"2009","unstructured":"Chavey C, Lazennec G, Lagarrigue S, Clape C, Iankova I, Teyssier J, Annicotte JS, Schmidt J, Mataki C, Yamamoto H, et al. CXC ligand 5 is an adipose-tissue derived factor that links obesity to insulin resistance. Cell Metab. 2009;9(4):339\u201349.","journal-title":"Cell Metab"},{"issue":"5","key":"1564_CR57","doi-asserted-by":"publisher","first-page":"449","DOI":"10.3390\/biomedicines9050449","volume":"9","author":"J Henkel","year":"2021","unstructured":"Henkel J, Klauder J, Statz M, Wohlenberg AS, Kuipers S, Vahrenbrink M, Puschel GP. Enhanced palmitate-induced interleukin-8 formation in human macrophages by insulin or prostaglandin E2. Biomedicines. 2021;9(5):449.","journal-title":"Biomedicines"},{"key":"1564_CR58","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1476-9255-6-25","volume":"6","author":"C Kobashi","year":"2009","unstructured":"Kobashi C, Asamizu S, Ishiki M, Iwata M, Usui I, Yamazaki K, Tobe K, Kobayashi M, Urakaze M. Inhibitory effect of IL-8 on insulin action in human adipocytes via MAP kinase pathway. J Inflamm. 2009;6:25.","journal-title":"J Inflamm"},{"issue":"9","key":"1564_CR59","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.3390\/cells10092324","volume":"10","author":"V Castelli","year":"2021","unstructured":"Castelli V, Brandolini L, d\u2019Angelo M, Giorgio C, Alfonsetti M, Cocchiaro P, Lombardi F, Cimini A. Allegretti M: CXCR1\/2 inhibitor ladarixin ameliorates the insulin resistance of 3T3-L1 adipocytes by inhibiting inflammation and improving insulin signaling. Cells. 2021;10(9):2324.","journal-title":"Cells"},{"issue":"2","key":"1564_CR60","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1172\/JCI200422422","volume":"114","author":"JD Browning","year":"2004","unstructured":"Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest. 2004;114(2):147\u201352.","journal-title":"J Clin Invest"},{"issue":"3","key":"1564_CR61","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.jhep.2021.10.013","volume":"76","author":"PK Luukkonen","year":"2022","unstructured":"Luukkonen PK, Qadri S, Ahlholm N, Porthan K, Mannisto V, Sammalkorpi H, Penttila AK, Hakkarainen A, Lehtimaki TE, Gaggini M, et al. Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease. J Hepatol. 2022;76(3):526\u201335.","journal-title":"J Hepatol"},{"issue":"3","key":"1564_CR62","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/hep.23784","volume":"52","author":"BA Neuschwander-Tetri","year":"2010","unstructured":"Neuschwander-Tetri BA, Clark JM, Bass NM, Van Natta ML, Unalp-Arida A, Tonascia J, Zein CO, Brunt EM, Kleiner DE, McCullough AJ, et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology. 2010;52(3):913\u201324.","journal-title":"Hepatology"},{"issue":"8","key":"1564_CR63","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1161\/ATVBAHA.112.250019","volume":"32","author":"MA Ramos-Roman","year":"2012","unstructured":"Ramos-Roman MA, Lapidot SA, Phair RD, Parks EJ. Insulin activation of plasma nonesterified fatty acid uptake in metabolic syndrome. Arterioscler Thromb Vasc Biol. 2012;32(8):1799\u2013808.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"1564_CR64","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1172\/JCI77812","volume":"126","author":"VT Samuel","year":"2016","unstructured":"Samuel VT, Shulman GI. The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J Clin Invest. 2016;126(1):12\u201322.","journal-title":"J Clin Invest"},{"issue":"2","key":"1564_CR65","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/brv.12178","volume":"91","author":"FW Sanders","year":"2016","unstructured":"Sanders FW, Griffin JL. De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose. Biol Rev Camb Philos Soc. 2016;91(2):452\u201368.","journal-title":"Biol Rev Camb Philos Soc"},{"issue":"6","key":"1564_CR66","doi-asserted-by":"publisher","first-page":"E1205","DOI":"10.1152\/ajpendo.00117.2019","volume":"317","author":"S Cui","year":"2019","unstructured":"Cui S, Qiao L, Yu S, Men L, Li Y, Li F, Du J. The antagonist of CXCR1 and CXCR2 protects db\/db mice from metabolic diseases through modulating inflammation. Am J Physiol Endocrinol Metab. 2019;317(6):E1205\u201317.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"33","key":"1564_CR67","doi-asserted-by":"publisher","first-page":"4904","DOI":"10.3748\/wjg.v25.i33.4904","volume":"25","author":"ML Boland","year":"2019","unstructured":"Boland ML, Oro D, Tolbol KS, Thrane ST, Nielsen JC, Cohen TS, Tabor DE, Fernandes F, Tovchigrechko A, Veidal SS, et al. Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: impact of dietary fat source. World J Gastroenterol. 2019;25(33):4904\u201320.","journal-title":"World J Gastroenterol"},{"issue":"5","key":"1564_CR68","doi-asserted-by":"publisher","first-page":"G825","DOI":"10.1152\/ajpgi.00145.2011","volume":"301","author":"M Charlton","year":"2011","unstructured":"Charlton M, Krishnan A, Viker K, Sanderson S, Cazanave S, McConico A, Masuoko H, Gores G. Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol. 2011;301(5):G825-834.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"1","key":"1564_CR69","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s12876-020-01356-2","volume":"20","author":"HH Hansen","year":"2020","unstructured":"Hansen HH, Aegidius HM, Oro D, Evers SS, Heeboll S, Eriksen PL, Thomsen KL, Bengtsson A, Veidal SS, Feigh M, et al. Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis. BMC Gastroenterol. 2020;20(1):210.","journal-title":"BMC Gastroenterol"},{"issue":"5","key":"1564_CR70","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1002\/hep.30672","volume":"70","author":"A Cheung","year":"2019","unstructured":"Cheung A, Neuschwander-Tetri BA, Kleiner DE, Schabel E, Rinella M, Harrison S, Ratziu V, Sanyal AJ, Loomba R, Jeannin Megnien S, et al. Defining improvement in nonalcoholic steatohepatitis for treatment trial endpoints: recommendations from the liver forum. Hepatology. 2019;70(5):1841\u201355.","journal-title":"Hepatology"},{"issue":"6","key":"1564_CR71","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","volume":"158","author":"RS Taylor","year":"2020","unstructured":"Taylor RS, Taylor RJ, Bayliss S, Hagstrom H, Nasr P, Schattenberg JM, Ishigami M, Toyoda H, Wai-Sun Wong V, Peleg N, et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterology. 2020;158(6):1611-1625 e1612.","journal-title":"Gastroenterology"},{"issue":"10","key":"1564_CR72","doi-asserted-by":"publisher","first-page":"e1912565","DOI":"10.1001\/jamanetworkopen.2019.12565","volume":"2","author":"DE Kleiner","year":"2019","unstructured":"Kleiner DE, Brunt EM, Wilson LA, Behling C, Guy C, Contos M, Cummings O, Yeh M, Gill R, Chalasani N, et al. Association of histologic disease activity with progression of nonalcoholic fatty liver disease. JAMA Netw Open. 2019;2(10):e1912565.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"1564_CR73","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3390\/ijms19020379","volume":"19","author":"S Sciacchitano","year":"2018","unstructured":"Sciacchitano S, Lavra L, Morgante A, Ulivieri A, Magi F, De Francesco GP, Bellotti C, Salehi LB, Ricci A. Galectin-3: one molecule for an alphabet of diseases, from A to Z. Int J Mol Sci. 2018;19(2):329.","journal-title":"Int J Mol Sci"},{"key":"1564_CR74","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3389\/fcell.2018.00150","volume":"6","author":"W Hou","year":"2018","unstructured":"Hou W, Syn WK. Role of metabolism in hepatic stellate cell activation and fibrogenesis. Front Cell Dev Biol. 2018;6:150.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"1564_CR75","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/(SICI)1521-4141(199801)28:01<164::AID-IMMU164>3.0.CO;2-S","volume":"28","author":"M Wolf","year":"1998","unstructured":"Wolf M, Delgado MB, Jones SA, Dewald B, Clark-Lewis I, Baggiolini M. Granulocyte chemotactic protein 2 acts via both IL-8 receptors, CXCR1 and CXCR2. Eur J Immunol. 1998;28(1):164\u201370.","journal-title":"Eur J Immunol"},{"issue":"1","key":"1564_CR76","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1046\/j.1432-1327.1998.2550067.x","volume":"255","author":"A Wuyts","year":"1998","unstructured":"Wuyts A, Proost P, Lenaerts JP, Ben-Baruch A, Van Damme J, Wang JM. Differential usage of the CXC chemokine receptors 1 and 2 by interleukin-8, granulocyte chemotactic protein-2 and epithelial-cell-derived neutrophil attractant-78. Eur J Biochem. 1998;255(1):67\u201373.","journal-title":"Eur J Biochem"},{"issue":"9","key":"1564_CR77","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1021\/bi961999z","volume":"36","author":"A Wuyts","year":"1997","unstructured":"Wuyts A, Van Osselaer N, Haelens A, Samson I, Herdewijn P, Ben-Baruch A, Oppenheim JJ, Proost P, Van Damme J. Characterization of synthetic human granulocyte chemotactic protein 2: usage of chemokine receptors CXCR1 and CXCR2 and in vivo inflammatory properties. Biochemistry. 1997;36(9):2716\u201323.","journal-title":"Biochemistry"},{"issue":"47","key":"1564_CR78","doi-asserted-by":"publisher","first-page":"29355","DOI":"10.1016\/S0021-9258(18)43882-3","volume":"269","author":"CR Bozic","year":"1994","unstructured":"Bozic CR, Gerard NP, von Uexkull-Guldenband C, Kolakowski LF Jr, Conklyn MJ, Breslow R, Showell HJ, Gerard C. The murine interleukin 8 type B receptor homologue and its ligands. Expression and biological characterization. J Biol Chem. 1994;269(47):29355\u20138.","journal-title":"J Biol Chem"},{"issue":"4","key":"1564_CR79","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/0161-5890(93)90065-J","volume":"30","author":"DP Cerretti","year":"1993","unstructured":"Cerretti DP, Kozlosky CJ, Vanden Bos T, Nelson N, Gearing DP, Beckmann MP. Molecular characterization of receptors for human interleukin-8, GRO\/melanoma growth-stimulatory activity and neutrophil activating peptide-2. Mol Immunol. 1993;30(4):359\u201367.","journal-title":"Mol Immunol"},{"issue":"1","key":"1564_CR80","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.cyto.2005.02.005","volume":"31","author":"W Fu","year":"2005","unstructured":"Fu W, Zhang Y, Zhang J, Chen WF. Cloning and characterization of mouse homolog of the CXC chemokine receptor CXCR1. Cytokine. 2005;31(1):9\u201317.","journal-title":"Cytokine"},{"issue":"7","key":"1564_CR81","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.molimm.2005.06.043","volume":"43","author":"B Moepps","year":"2006","unstructured":"Moepps B, Nuesseler E, Braun M, Gierschik P. A homolog of the human chemokine receptor CXCR1 is expressed in the mouse. Mol Immunol. 2006;43(7):897\u2013914.","journal-title":"Mol Immunol"},{"issue":"16","key":"1564_CR82","doi-asserted-by":"publisher","first-page":"11658","DOI":"10.1074\/jbc.M607705200","volume":"282","author":"X Fan","year":"2007","unstructured":"Fan X, Patera AC, Pong-Kennedy A, Deno G, Gonsiorek W, Manfra DJ, Vassileva G, Zeng M, Jackson C, Sullivan L, et al. Murine CXCR1 is a functional receptor for GCP-2\/CXCL6 and interleukin-8\/CXCL8. J Biol Chem. 2007;282(16):11658\u201366.","journal-title":"J Biol Chem"},{"issue":"1","key":"1564_CR83","first-page":"40","volume":"9","author":"M Sharma","year":"2021","unstructured":"Sharma M, Premkumar M, Kulkarni AV, Kumar P, Reddy DN, Rao NP. Drugs for non-alcoholic steatohepatitis (NASH): quest for the holy grail. J Clin Transl Hepatol. 2021;9(1):40\u201350.","journal-title":"J Clin Transl Hepatol"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-022-01564-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-022-01564-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-022-01564-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T06:04:07Z","timestamp":1657692247000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-022-01564-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,12]]},"references-count":83,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1564"],"URL":"https:\/\/doi.org\/10.1186\/s12933-022-01564-y","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,12]]},"assertion":[{"value":"16 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were approved and conducted in accordance with the AALAC-certified Allegheny Health Network IACUC policies and standard operating procedures as well the AALAC-accredited Vanderbilt University Animal Care and Use Committee policies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to articipate"}},{"value":"No human studies or human tissues were used in this research study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Mantzoros reports grants, personal fees, and other from AltrixBio, Coherus Biosciences, and Novo Nordisk, personal fees and non-financial support from Ansh, Aegerion, California Walnut Commission, and personal fees from Amgen, Corcept, Lumos, GENFIT, Intercept, Regeneron, CardioMetabolic Health Conference and The Metabolic Institute of America.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"130"}}